Science Board to the Food and Drug Administration

Date, time, and place. March 28 and 29, 1996, 8:30 a.m., Sheraton National Hotel, North Ballroom, 900 South Orme St. (Columbia Pike and Washington Blvd.), Arlington, VA.

Type of meeting and contact person. Open committee discussion, March 28, 1996, 8:30 a.m. to 2:30 p.m.; open public hearing, 2:30 p.m. to 3:30 p.m., unless public participation does not last that long; open committee discussion, 3:30 p.m. to 5 p.m.; open committee discussion, March 29, 1996, 8:30 a.m. to 10:30 a.m.; open public hearing 10:30 a.m. to 11:30 a.m., unless public participation does not last that long; open committee discussion, 11:30 a.m. to 1:30 p.m. For the March 28, 1996, agenda contact Susan Homire, Office of Science (HF–33), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD, 20857, 301–827–3340; for the March 29, 1996, agenda contact Mary Gross, Office of External Affairs (HF–24), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD, 20857, 301–827–3440; or, FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Science Board to the Food and Drug Administration, code 12603.

General function of the board. The board shall provide advice primarily to the agency's Senior Science Advisor, and, as needed, to the Commissioner and other appropriate officials on specific complex and technical issues as well as emerging issues within the scientific community in industry and academia. Additionally, the board will provide advice to the agency on keeping pace with technical and scientific evolutions in the fields of regulatory science; on formulating an appropriate research agenda; and on upgrading its scientific and research facilities to keep pace with these changes. It will also provide the means for critical review of agency-sponsored intramural and extramural scientific research programs.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the board. Those desiring to make formal presentations must notify the contact person before March 14, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, and the names and addresses of proposed participants. Each presenter will be limited in time and not all requests to speak may be able to be accommodated. All written statements submitted in a timely fashion will be provided to the board.

Open board discussion. On March 28, 1996, the board will discuss issues related to the safety in the testing of biomaterials used in products regulated by FDA; including strategies by which the agency can prepare for new developments in biomaterials science and the use of novel materials in device and medical implant products. On March 29, 1996, the board will discuss financial disclosure by clinical investigators. For further information on the agenda of this meeting see a document entitled ''Financial Disclosure by Clinical Investigators; Reopening of the Comment Period and Notice of Meeting,'' published elsewhere in this issue of the Federal Register.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this Federal Register notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: February 16, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–4288 Filed 2–23–96; 8:45 am]

BILLING CODE 4160–01–F

National Institutes of Health

Alternative Medicine Program Advisory Council; Notice of Meeting

Pursuant to sec. 10(d) of the Federal Advisory Committee Act (FACA), as amended (Title 5, U.S.C. Appendix 2), notice is hereby given of the meeting of the Alternative Medicine Program Advisory Council on February 26, 1996, from 8 am to 5 pm and on February 27 from 8 am to 11 am in Conference Room 6, Building 31A, the National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland.

The entire meeting will be open to the public. The purpose of the meeting will be to discuss activities of the Office of Alternative Medicine and strategic planning for alternative medicine research. Attendance by the public will be limited to space available.

Ms. Beth Clay, Committee Management Officer, Office of Alternative Medicine, NIH, 6120 Executive Boulevard, Suite 450, Rockville, Maryland 20892–9904, phone (301) 594–1990, fax (301) 402–4741, E–Mail: bethclay@helix.nih.gov, will finish the meeting agenda, roster of committee members, and substantive program information upon request. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Clay at the above location immediately.

This notice is being published less than15 days prior to the meeting due to the partial shutdown of the Federal Government and resultant administrative difficulties, and the need to proceed with the meeting as scheduled to address important issues in a timely manner.

Dated: February 21, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–4357 Filed 2–23–96; 8:45 am]

BILLING CODE 4140–01–M

Substance Abuse and Mental Health Services Administration

Center for Substance Abuse Prevention; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the Drug Testing Advisory Board of the Center for Substance Abuse Prevention in March 1996.

The meeting agenda will include discussion of announcements and reports of administrative, legislative, and program developments. It will also include reviews of sensitive National Laboratory Certification Program (NLCP) internal operating procedures and program development issues. Therefore, a portion of this meeting will be closed to the public as determined by the Administrator, SAMHSA, in accordance with 5 U.S.C. 552b(c)(2), (4), and (6) and 5 U.S.C. Appendix 2, section 10(d).

A summary of this meeting and roster of committee members may be obtained from: Ms. Vera L. Jones, Committee Management Officer, CSAP, Rockwall II Building, Room 7A 140, 5600 Fishers Lane, Rockville, MD 20857, Telephone: (301) 443–9542.

Substantive program information may be obtained from the contact whose name, room number, and telephone number is listed below.

Committee Name: Drug Testing Advisory Board.

Meeting Date(s): March 27, 1996.

Place: Ramada Inn—Rockville, 1775 Rockville Pike, Rockville, Maryland 20857.

Open: March 27, 1996 8:30 a.m.–10:00 a.m.

Closed: March 27, 1996 10:00 a.m.—Adjournment.

Contact: Donna M. Bush, Ph.D.; Parklawn Building, Room 13A–54; Telephone: (301) 443–6014.

Dated: February 20, 1996.

Jeri Lipov,

Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 96–4231 Filed 2–23–96; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Availability of an Environmental Assessment and Receipt of an Application for an Incidental Take Permit From Brett Real Estate, Robinson Development Company, Incorporated, Orange Beach, Alabama—Correction

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice; correction.

SUMMARY: The Fish and Wildlife Service is correcting an error placed in the Notice of Availability of an Environmental Assessment and Receipt of an Application for an Incidental Take Permit from Brett Real Estate/Robinson Development Company, Incorporated, Orange Beach, Alabama, which appeared in the Federal Register on January 20, 1996 (61 FR 1400).

FOR FURTHER INFORMATION CONTACT: Mr. Rick G. Gooch at (404) 679–7110.

SUPPLEMENTARY INFORMATION: In January 19, 1996, the Service announced the availability of an Environmental Assessment and Receipt of an Application for an Incidental Take Permit from Brett Real Estate, Robinson Development Company, Incorporated (61 FR 1400). The permit number PRT–809898 was assigned to the application. Within the Supplementary Information of the original Federal Register notice, a statement was made that: ''The Applicant's property contains designated critical habitat for the Alabama beach mouse (ABM).'' Upon review of the designated critical habitat of the ABM (§ 17.95(a) of title 50, Code of Federal Regulations), it has been determined that the land encompassed by the pending application does not contain designated critical habitat for the ABM. The statement is in error and is not germane to the Service's review of the application for effects to the ABM. Comments on the application must be received on or before February 20, 1996.

Dated: February 20, 1996.

Jerome M. Butler,

Acting Regional Director.

[FR Doc. 96–4240 Filed 2–23–96; 8:45 am]

BILLING CODE 4310–55–M

Bureau of Land Management

[WY–930–5101–00–K012, WYW–128830]

Notice of Availability of the Final Environmental Impact Statement for the Express Pipeline

AGENCY: Bureau of Land Management, Interior.

SUMMARY: A Final Environmental Impact Statement (EIS) for Express Pipeline, Inc., to construct, operate, and maintain a 24-inch pipeline on public lands to transport crude oil between Wild Horse, Alberta, and Casper, Wyoming. A right-of-way grant for the pipeline to cross public lands in Montana, and Wyoming, would be issued by the Bureau of Land Management, Worland District, in accordance with Section 501 of the Federal Land Policy and Management Act of 1976.

The Bureau of Land Management and the Montana Department of Environmental Quality (DEQ) are co-leads for the EIS. Other cooperating agencies for the EIS include the Army Corps of Engineers and the Bureau of Reclamation. The final EIS document was prepared by Greystone, a third-party contractor, under the provisions of Section 102(2)(C) of the National Environmental Policy Act (NEPA) of 1969, as amended. The EIS has been prepared in an abbreviated format; that is, the alternatives considered in the draft EIS and the environmental effects of those alternatives, have not been reprinted in the EIS. It is necessary, therefore, to use both the draft and final documents for a complete review. Copies of the draft EIS and the final EIS can be obtained from the BLM's Worland District Office or the Montana Department of Environmental Quality at the addresses listed below.